Chu Bichat Claude Bernard
Paris, 75018, France
NCT Number: NCT00472667
The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, 75018, France
Clinical and laboratory signs are neither specific nor sensitive for diagnosis of sepsis in critically-ill patients. Because delaying antimicrobial therapy may be deleterious, broad-spectrum antibiotics are widely used in ICU -patients, even when they are not needed. In addition, only few well-designed studies concerning the duration of antibiotic treatment have been so far published. Consequently, many patients received antibiotics during the ICU stay. Many studies have shown that exposure to antibiotics, the so called "selection pressure" is an independent risk factor for acquisition of resistance in individual patients. Therefore, reducing antibiotic use is probably necessary to control antibiotic resistance. Many clinical studies have shown that procalcitonin (PCT) is able to distinguish the inflammatory response to infection from other types of inflammation and to distinguish bacterial from viral infections. Recent studies have shown that PCT guidance substantially and safely reduced antibiotic overuse in patients with lower respiratory tract infections. We aimed to evaluate the role of PCT in reducing the use of antibiotics in ICU adult patients. The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Procalcitonin guided strategy
Time frame: assessed 28 days after inclusion
Time frame: at Day 28 and Day 60
Time frame: between D1 and D28
Time frame: during the stay at the hospital
Time frame: between D1 and D28
Time frame: at D28
Time frame: between D1 and D28
Time frame: between D1 and D28
Time frame: between D1 and D28
Assistance Publique - Hôpitaux de Paris
Other
Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients
Acronym: PRORATA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00353158
Bacterial Infections, Bacterial Infections and Mycoses
Bethesda, Maryland, United States
View Trial DetailsNCT05217537
Bacterial Infections, Bacterial Infections and Mycoses
Little Rock, Arkansas, United States
View Trial DetailsNCT03424525
Bacterial Infections, Bacterial Infections and Mycoses
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06079775
Bacterial Infections, Bacterial Infections and Mycoses
Adelaide, South Australia, Australia
View Trial Details